Novavax Completes Construction of Vaccine Production Facility in India
CPL Biologicals, a joint venture of Cadila Pharmaceuticals Ltd. (Ahmendabad, India) and Novavax, Inc. (Rockville, MD), has completed construction of its vaccine facility in Dholka, India.
CPL Biologicals (CPLB), a joint venture of Cadila Pharmaceuticals Ltd. (Ahmendabad, India) and Novavax, Inc. (Rockville, MD), has completed construction of its vaccine facility in Dholka, India. CPLB will commence equipment and installation validation this month so the facility will conform to global standards for production of vaccines for human use.
The new facility uses state-of-the-art equipment for the potential production of up to 60 million doses of vaccines every year. The facility plans to produce seasonal and pandemic flu vaccines based on Novavax's virus-like particle (VLP) technology that enables the rapid development and production of vaccines without the use of live virus.
In addition to vaccine production, CPLB also is focused on the development, manufacture, and sale of biosimilars and diagnostic kits.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
